Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;27(1):50-57.
doi: 10.1111/jns.12477. Epub 2021 Dec 9.

A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease

Alexander Martin Rossor  1 , Mahima Kapoor  1 , Henny Wellington  2   3 , Emily Spaulding  4   5 , James N Sleigh  1   3 , Robert W Burgess  4   5 , Matilde Laura  1 , Henrik Zetterberg  2   3   6   7 , Alexa Bacha  8 , Xingyao Wu  8 , Amanda Heslegrave  2   3 , Michael E Shy  8 , Mary M Reilly  1
Affiliations

A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease

Alexander Martin Rossor et al. J Peripher Nerv Syst. 2022 Mar.

Abstract

Advances in genetic technology and small molecule drug development have paved the way for clinical trials in Charcot-Marie-Tooth disease (CMT); however, the current FDA-approved clinical trial outcome measures are insensitive to detect a meaningful clinical response. There is, therefore, a need to identify sensitive outcome measures or clinically relevant biomarkers. The aim of this study was to further evaluate plasma neurofilament light chain (NFL) as a disease biomarker in CMT. Plasma NFL was measured using SIMOA technology in both a cross-sectional study of a US cohort of CMT patients and longitudinally over 6 years in a UK CMT cohort. In addition, plasma NFL was measured longitudinally in two mouse models of CMT2D. Plasma concentrations of NFL were increased in a US cohort of patients with CMT1B, CMT1X and CMT2A but not CMT2E compared with controls. In a separate UK cohort, over a 6-year interval, there was no significant change in plasma NFL concentration in CMT1A or HSN1, but a small but significant reduction in patients with CMT1X. Plasma NFL was increased in wild type compared to GARSC201R mice. There was no significant difference in plasma NFL in GARSP278KY compared to wild type mice. In patients with CMT1A, the small difference in cross-sectional NFL concentration vs healthy controls and the lack of change over time suggests that plasma NFL may lack sufficient sensitivity to detect a clinically meaningful treatment response in adulthood.

Keywords: Charcot-Marie-Tooth disease; biomarkers; neurofilament.

PubMed Disclaimer

References

REFERENCES

    1. Foley C, Schofield I, Eglon G, Bailey G, Chinnery PF, Horvath R. Charcot-Marie-Tooth disease in Northern England. J Neurol Neurosurg Psychiatry. 2012;83(5):572-573. doi:10.1136/jnnp-2011-300285
    1. Stavrou M, Sargiannidou I, Georgiou E, Kagiava A, Kleopa KA. Emerging therapies for Charcot-Marie-Tooth inherited neuropathies. Int J Mol Sci. 2021;22(11):6048. doi:10.3390/ijms22116048
    1. Rossor A. Are we prepared for clinical trials in Charcot-MarieTooth disease? Brain Res. 2019;1729:146625. doi:10.1016/j.brainres.2019.146625
    1. Johnson NE, Heatwole C, Creigh P, et al. The Charcot-Marie-Tooth Health Index: evaluation of a patient-reported outcome. Ann Neurol. 2018;84(2):225-233. doi:10.1002/ana.25282
    1. Eichinger K, Burns J, Cornett K, et al. The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Neurology. 2018;91(15):e1381-e1384. doi:10.1212/WNL.0000000000006323

Publication types

LinkOut - more resources